ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SHMN SOHM Inc (PK)

0.001
0.00 (0.00%)
29 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
SOHM Inc (PK) USOTC:SHMN OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.001 0.0008 0.001 0.001 0.001 0.001 27,000 12:16:40

SOHM Inc.: Rated ‘Speculative Buy,’ Target Price $0.33 by Beacon Equity Research

11/06/2009 12:00pm

Business Wire


SOHM (PK) (USOTC:SHMN)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more SOHM (PK) Charts.

SOHM Inc. (Pink Sheets: SHMN) has been rated Speculative Buy with a price target of $0.33 by Beacon Analyst, Victor Sula, Ph.D.

The full report is available at http://www.beaconequity.com.

Anyone interested in receiving alerts regarding SHMN research should e-mail members@beaconequity.com with “SHMN” in the subject line.

In the report, the analyst writes, “SHMN produces high quality pharmaceuticals at a low price and sells them to emerging market countries where drugs are greatly needed and not being served by the major generic drug manufacturers. The Company has a pharmaceutical manufacturing facility in India offering the lowest production costs available without sacrificing the quality of the drugs. SHMN sells its generic pharmaceuticals through a targeted approach in emerging markets in Africa, Latin America, and Southeast Asia which currently offer the fastest growth rates for drugs globally.”

The Beacon analyst also notes, “Based on management business outlook and our understanding of SHMN’s business model we expect the Company to report revenues of $1.8 million in 2009, $4.5 million in 2010 and $7.6 million in 2011. … Over the longer-term, we expect SHNM to maintain double-digits growth rates for both revenue and earnings, driven mainly by strong organic growth and acquisitions.”

Other global specialty pharmaceutical companies include: Watson Pharmaceuticals Inc. (NYSE: WPI), Mylan Inc. (Nasdaq: MYL), Par Pharmaceutical Companies Inc. (NYSE: PRX) and Teva Pharmaceutical Industries (Nasdaq: TEVA).

BeaconEquity Research Disclosure

Analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. BeaconEquity.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BlueWave Advisors, LLC has been compensated fifty thousand dollars from Blue Horseshoe Entertainment, a shareholder of SHMN, as a marketing budget to manage a comprehensive investor awareness program including the creation and distribution of this report as well as other investor relations efforts. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Please read our report and visit our Web site, BeaconEquity.com, for complete disclosures.

1 Year SOHM (PK) Chart

1 Year SOHM (PK) Chart

1 Month SOHM (PK) Chart

1 Month SOHM (PK) Chart

Your Recent History

Delayed Upgrade Clock